Janux Therapeutics (NASDAQ:JANX) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

Janux Therapeutics (NASDAQ:JANX) had its price target increased by investment analysts at Stifel Nicolaus from $70.00 to $115.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ target price points to a potential upside of 84.62% from the company’s current price.

Other equities analysts have also recently issued reports about the stock. Leerink Partnrs raised shares of Janux Therapeutics to a “strong-buy” rating in a research note on Friday, November 22nd. Wedbush reiterated an “outperform” rating and issued a $74.00 target price on shares of Janux Therapeutics in a research note on Thursday, August 8th. William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a research report on Tuesday. BTIG Research boosted their target price on Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $100.00 price target on shares of Janux Therapeutics in a report on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Janux Therapeutics presently has an average rating of “Buy” and an average target price of $77.90.

Janux Therapeutics Stock Up 55.0 %

JANX traded up $22.11 during trading hours on Tuesday, hitting $62.29. 5,163,446 shares of the company’s stock were exchanged, compared to its average volume of 737,807. The stock has a market cap of $3.27 billion, a price-to-earnings ratio of -53.24 and a beta of 3.30. Janux Therapeutics has a 1-year low of $7.79 and a 1-year high of $71.25. The stock’s 50-day moving average is $49.81 and its two-hundred day moving average is $45.77.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The company had revenue of $0.44 million during the quarter, compared to the consensus estimate of $1.50 million. The business’s revenue for the quarter was down 82.6% on a year-over-year basis. On average, equities research analysts anticipate that Janux Therapeutics will post -1.35 EPS for the current year.

Insider Activity at Janux Therapeutics

In other Janux Therapeutics news, CEO David Alan Campbell sold 25,000 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $51.60, for a total transaction of $1,290,000.00. Following the transaction, the chief executive officer now owns 257,054 shares in the company, valued at $13,263,986.40. This trade represents a 8.86 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Ventures Xi L.P. Avalon sold 2,182 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $42.33, for a total value of $92,364.06. Following the sale, the insider now directly owns 7,000 shares in the company, valued at approximately $296,310. This trade represents a 23.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 445,610 shares of company stock worth $20,578,666. Corporate insiders own 29.40% of the company’s stock.

Institutional Trading of Janux Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Franklin Resources Inc. raised its position in Janux Therapeutics by 64.5% during the third quarter. Franklin Resources Inc. now owns 18,983 shares of the company’s stock valued at $937,000 after purchasing an additional 7,442 shares in the last quarter. Virtu Financial LLC increased its stake in shares of Janux Therapeutics by 48.0% in the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock valued at $339,000 after purchasing an additional 2,419 shares during the last quarter. Neo Ivy Capital Management acquired a new position in shares of Janux Therapeutics during the 3rd quarter worth $940,000. Geode Capital Management LLC lifted its position in shares of Janux Therapeutics by 6.2% during the 3rd quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock worth $30,107,000 after buying an additional 38,490 shares during the last quarter. Finally, Barclays PLC boosted its stake in Janux Therapeutics by 496.5% in the third quarter. Barclays PLC now owns 174,061 shares of the company’s stock valued at $7,907,000 after buying an additional 144,883 shares in the last quarter. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.